Chih‐Hsi S. Kuo

2.6k total citations
72 papers, 954 citations indexed

About

Chih‐Hsi S. Kuo is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Chih‐Hsi S. Kuo has authored 72 papers receiving a total of 954 indexed citations (citations by other indexed papers that have themselves been cited), including 58 papers in Pulmonary and Respiratory Medicine, 46 papers in Oncology and 11 papers in Molecular Biology. Recurrent topics in Chih‐Hsi S. Kuo's work include Lung Cancer Treatments and Mutations (45 papers), Colorectal Cancer Treatments and Studies (22 papers) and Lung Cancer Research Studies (18 papers). Chih‐Hsi S. Kuo is often cited by papers focused on Lung Cancer Treatments and Mutations (45 papers), Colorectal Cancer Treatments and Studies (22 papers) and Lung Cancer Research Studies (18 papers). Chih‐Hsi S. Kuo collaborates with scholars based in Taiwan, United Kingdom and United States. Chih‐Hsi S. Kuo's co-authors include Cheng‐Ta Yang, Ping‐Chih Hsu, Yike Guo, Yi‐Lung Chen, Kian Fan Chung, Ian M. Adcock, Stelios Pavlidis, Yueh‐Fu Fang, Anthony Rowe and Peter J. Sterk and has published in prestigious journals such as Journal of Clinical Oncology, Scientific Reports and Clinical Cancer Research.

In The Last Decade

Chih‐Hsi S. Kuo

68 papers receiving 944 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Chih‐Hsi S. Kuo Taiwan 16 607 409 263 158 150 72 954
P J George United Kingdom 17 503 0.8× 439 1.1× 104 0.4× 134 0.8× 263 1.8× 41 1.1k
Wolfgang Gesierich Germany 14 824 1.4× 532 1.3× 69 0.3× 101 0.6× 199 1.3× 63 1.4k
Kakuhiro Yamaguchi Japan 15 470 0.8× 222 0.5× 101 0.4× 65 0.4× 96 0.6× 93 751
Yuko Waseda Japan 18 550 0.9× 214 0.5× 138 0.5× 68 0.4× 111 0.7× 58 937
Nalan Neşe Türkiye 15 317 0.5× 154 0.4× 191 0.7× 22 0.1× 160 1.1× 57 729
Mark Farrugia United States 15 277 0.5× 172 0.4× 43 0.2× 45 0.3× 234 1.6× 69 745
Chuanbo Zang United States 11 95 0.2× 165 0.4× 210 0.8× 386 2.4× 80 0.5× 42 1.3k
J.M. Gornet France 11 182 0.3× 359 0.9× 75 0.3× 42 0.3× 35 0.2× 24 801
Eric Lamarre United States 16 202 0.3× 374 0.9× 52 0.2× 31 0.2× 137 0.9× 87 977
Hidenori Mukaida Japan 14 382 0.6× 277 0.7× 47 0.2× 25 0.2× 120 0.8× 74 905

Countries citing papers authored by Chih‐Hsi S. Kuo

Since Specialization
Citations

This map shows the geographic impact of Chih‐Hsi S. Kuo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chih‐Hsi S. Kuo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chih‐Hsi S. Kuo more than expected).

Fields of papers citing papers by Chih‐Hsi S. Kuo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chih‐Hsi S. Kuo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chih‐Hsi S. Kuo. The network helps show where Chih‐Hsi S. Kuo may publish in the future.

Co-authorship network of co-authors of Chih‐Hsi S. Kuo

This figure shows the co-authorship network connecting the top 25 collaborators of Chih‐Hsi S. Kuo. A scholar is included among the top collaborators of Chih‐Hsi S. Kuo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chih‐Hsi S. Kuo. Chih‐Hsi S. Kuo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Umemura, Shigeki, Chih‐Hsi S. Kuo, Virote Sriuranpong, et al.. (2024). Clinical impact of the rapid genomic screening platform for non-small cell lung cancer in Asia-Pacific (LC-SCRUM-AP).. Journal of Clinical Oncology. 42(16_suppl). 8637–8637.
2.
3.
4.
Huang, Chi‐Hsien, Chin‐Chou Wang, Fu‐Tsai Chung, et al.. (2023). Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC. Scientific Reports. 13(1). 20323–20323. 8 indexed citations
5.
Wu, Chen‐Te, Chen‐Te Wu, Ping‐Chih Hsu, et al.. (2023). Comprehensive assessment of pretreatment sarcopenia impacts on patients with EGFR‐mutated NSCLC treated with afatinib. Thoracic Cancer. 14(25). 2548–2557. 3 indexed citations
6.
Rotow, Julia, Jyoti D. Patel, Helena A. Yu, et al.. (2023). Osimertinib and Selpercatinib Efficacy, Safety, and Resistance in a Multicenter, Prospectively Treated Cohort of EGFR -Mutant and RET Fusion-Positive Lung Cancers. Clinical Cancer Research. 29(16). 2979–2987. 26 indexed citations
7.
8.
Chang, John Wen‐Cheng, Chen‐Yang Huang, Yueh‐Fu Fang, et al.. (2022). Risk Stratification Using a Novel Nomogram for 2190 EGFR-Mutant NSCLC Patients Receiving the First or Second Generation EGFR-TKI. Cancers. 14(4). 977–977. 11 indexed citations
9.
Hsu, Ping‐Chih, John Wen‐Cheng Chang, Chen‐Yang Huang, et al.. (2022). Sequential treatment in advanced non–small cell lung cancer harboring EGFR mutations. Therapeutic Advances in Respiratory Disease. 16. 2673712059–2673712059. 10 indexed citations
10.
Chiu, Chi‐Tsun, Chih‐Liang Wang, Tsung‐Ying Yang, et al.. (2022). Overall Survival Improvement in Patients with Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer and Bone Metastasis Treated with Denosumab. Cancers. 14(14). 3470–3470. 9 indexed citations
11.
Kuo, Chih‐Hsi S., Chi‐Hsien Huang, Chin‐Chou Wang, et al.. (2022). Afatinib Treatment Alone or with Bevacizumab in a Real-World Cohort of Non-Small Cell Lung Cancer Patients with Epidermal Growth Factor Receptor Mutation. Cancers. 14(2). 316–316. 7 indexed citations
12.
Lin, Yu‐Ching, Li‐Chung Chiu, Shih‐Hong Li, et al.. (2022). Comparison of afatinib and erlotinib combined with bevacizumab in untreated stage IIIB/IV epidermal growth factor receptor-mutated lung adenocarcinoma patients: a multicenter clinical analysis study. Therapeutic Advances in Medical Oncology. 14. 4287525310–4287525310. 7 indexed citations
13.
Huang, Chi‐Hsien, Chin‐Chou Wang, Chien‐Ying Liu, et al.. (2021). First- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors in a large, real-world cohort of patients with non-small cell lung cancer. Therapeutic Advances in Medical Oncology. 13. 4277447742–4277447742. 17 indexed citations
14.
Kuo, Chih‐Hsi S., Chin‐Chou Wang, John Wen‐Cheng Chang, et al.. (2021). A retrospective study of alectinib versus ceritinib in patients with advanced non–small-cell lung cancer of anaplastic lymphoma kinase fusion in whom crizotinib treatment failed. BMC Cancer. 21(1). 309–309. 5 indexed citations
15.
Chiu, Li‐Chung, Shu‐Min Lin, Yu‐Lun Lo, et al.. (2021). Immunotherapy and Vaccination in Surgically Resectable Non-Small Cell Lung Cancer (NSCLC). Vaccines. 9(7). 689–689. 14 indexed citations
16.
Wang, Chin‐Chou, Chien‐Ying Liu, Chih‐Liang Wang, et al.. (2020). Consolidation treatment of durvalumab after chemoradiation in real‐world patients with stage III unresectable non‐small cell lung cancer. Thoracic Cancer. 11(6). 1541–1549. 28 indexed citations
17.
Kuo, Chih‐Hsi S., Chi‐Hsien Huang, Chien‐Ying Liu, et al.. (2019). Prior EGFR-TKI Treatment in EGFR-Mutated NSCLC Affects the Allele Frequency Fraction of Acquired T790M and the Subsequent Efficacy of Osimertinib. Targeted Oncology. 14(4). 433–440. 10 indexed citations
18.
Chang, Yu‐Chen, et al.. (2019). The Prevalence of PD-L1 Expression in Lung Cancer. 4(1). 6 indexed citations
19.
Huang, Shih‐Hao, Chin‐Chou Wang, Chien‐Ying Liu, et al.. (2019). Front‐line treatment of ceritinib improves efficacy over crizotinib for Asian patients with anaplastic lymphoma kinase fusion NSCLC: The role of systemic progression control. Thoracic Cancer. 10(12). 2274–2281. 3 indexed citations
20.
Chung, Fu‐Tsai, Shu‐Min Lin, Chun-Liang Chou, et al.. (2013). Complications of airway self-expandable metallic stent in benign airway diseases. Advances in Bioscience and Biotechnology. 4(1). 113–117. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by P J George Breakdown of academic impact, for papers by Wolfgang Gesierich Breakdown of academic impact, for papers by Kakuhiro Yamaguchi Breakdown of academic impact, for papers by Yuko Waseda Breakdown of academic impact, for papers by Nalan Neşe Breakdown of academic impact, for papers by Mark Farrugia Breakdown of academic impact, for papers by Chuanbo Zang Breakdown of academic impact, for papers by J.M. Gornet Breakdown of academic impact, for papers by Eric Lamarre Breakdown of academic impact, for papers by Hidenori Mukaida
Rankless by CCL
2026